Desperate patients get early access to promising drug
NCT ID NCT04745637
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides early access to the drug ruxolitinib for people with serious or life-threatening conditions like certain blood cancers, severe COVID-19, or graft-versus-host disease. It is for patients who have no other treatment options and cannot join a clinical trial. The goal is to offer potential benefit when standard therapies are not available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug outperform standard care for rare blood cancers?
- Can a new pill tame myelofibrosis?
- Scientists hunt for immune cells that could lead to new MPN therapies
- COVID ventilator infection study pulled before start
- Momelotinib access expanded for myelofibrosis patients in Long-Term safety study
- New drug ZE74-0282 targets rare blood cancers in early trial